PA
SMMT icon

Profund Advisors’s Summit Therapeutics SMMT Stock Holding History

Profund Advisors’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.46M Sell
100,549
-12,377
-11% -$219K 0.04% 274
2026
Q1 		$2.14M Buy
112,926
+9,165
+9% +$148K 0.08% 184
2025
Q4 		$1.81M Buy
103,761
+33,828
+48% +$636K 0.06% 235
2025
Q3 		$1.44M Buy
69,933
+30,293
+76% +$735K 0.05% 253
2025
Q2 		$844K Sell
39,640
-7,544
-16% -$172K 0.03% 334
2025
Q1 		$910K Sell
47,184
-12,093
-20% -$243K 0.04% 312
2024
Q4 		$1.06M Buy
59,277
+36,958
+166% +$716K 0.04% 286
2024
Q3 		$489K Sell
22,319
-8,883
-28% -$124K 0.02% 543
2024
Q2 		$243K Sell
31,202
-69,813
-69% -$377K 0.01% 853
2024
Q1 		$418K Buy
+101,015
New +$402K 0.02% 665

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Profund Advisors's SMMT Position: Q2 2026 in Review

Profund Advisors reduced its Summit Therapeutics (SMMT) stake by 11% in Q2 2026, selling an estimated $219K and leaving 100,549 shares worth $1.46M. The position accounts for 0.04% of the portfolio, ranked #274.

Profund Advisors first reported a position in SMMT in Q1 2024 and has held it in 10 quarters since. The position peaked at $2.14M in Q1 2026. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Profund Advisors held 100,549 shares of Summit Therapeutics worth $1.46M as of Q2 2026.
  • Profund Advisors sold 12,377 Summit Therapeutics shares in Q2 2026, an estimated $219K.
  • Summit Therapeutics made up 0.04% of Profund Advisors's portfolio in Q2 2026, its #274 holding.
  • Profund Advisors first reported a position in Summit Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • Profund Advisors's Summit Therapeutics position peaked at $2.14M in Q1 2026.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.